Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Macugen for Visual Function in Neovascular AMD (PERSPECTIVES)
NCT00327470Phase 4Terminated
- Sponsor
- Pfizer
- Start
- Jul 2006
- Primary completion
- Aug 2009
- Modality
- Antisense DNA, RNA Aptamers, Small Interfering RNA (siRNA)
- Countries
- 15
01
Overview
A Phase 4 trial of pegaptanib sodium in neovascular age-related macular degeneration (NVAMD), sponsored by Pfizer. Started Jul 2006; status: terminated.
02
Drugs
pegaptanib sodium
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT00327470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00327470.